INTRODUCTION
According to Datamonitor's estimate, nearly 423,000 new cases of SCLC and
NSCLC are expected to be diagnosed in the seven major pharmaceutical markets in
2003. Despite the high level of pharmaceutical interest, there are significant
unmet needs in the disease in terms of poor survival. This report examines the
current diagnosis and treatment trends of lung cancer in the seven major
markets.
SCOPE OF THE REPORT
- Analysis of Lung cancer treatment based on a survey of 152 clinical
oncologists and pulmonologists in the 7 major markets
- Diagnosis patterns of SCLC and NSCLC, including stage distribution and
physician types responsible for diagnosis
- Percentage use of various treatment modalities for SCLC and NSCLC by stage
REPORT HIGHLIGHTS
Third-generation cytotoxics, such as gemcitabine, vinorelbine and paclitaxel,
are increasingly being prescribed to SCLC patients. Having reached an efficacy
plateau with cisplatin and etoposide regimen, Datamonitor believes that
physicians will increasingly experiment with third-generation chemotherapy that
have proven to be effective in NSCLC.
Cisplatin plus Campto (irinotecan) is
the gold-standard regimen for extensive SCLC in Japan, based on the results of a
Japanese trial. Physicians in the US and Europe are generally skeptical of the
regimen and it will not see a wide uptake until the results are replicated in a
Western clinical trial.
Aventis' Taxotere (docetaxel) has the potential to
become the gold-standard first-line therapy for NSCLC in the US. However,
Datamonitor believes that this is unlikely to be the case in the European
markets, where Lilly's Gemzar (gemcitabine) and Pierre Fabre/GSK's Navelbine (vinorelbine)
will continue to dominate the NSCLC market.
KEY REASONS TO BUY THIS REPORT
- Assess the number of drug-treated population of lung cancer in the seven
major markets
- Enhance your commercial positioning by understanding the dynamics of
current lung cancer drugs
View Cart
